{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-041571","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2021-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.384561+00:00","generated_at":"2026-06-29T21:15:32.396041+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Enanta reports Q3 fiscal 2021 net loss of $24.0M; nominates COVID-19 protease inhibitor EDP-235","bullets":["Royalty revenue $21.6M from AbbVie's HCV regimen; net loss $24.0M ($1.19/sh) vs loss $14.3M ($0.71/sh) year ago.","Cash and securities $372.5M; R&D expenses increased to $47.0M from $34.7M.","Nominated EDP-235 oral protease inhibitor for SARS-CoV-2; Phase 1 study planned for early 2022.","Positive Phase 1b data for EDP-514 in viremic HBV patients: mean HBV DNA reduction 3.3 logs.","Planned retirement of CMO Nathalie Adda, M.D. in February 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-041571","json":"https://secwatch.observer/filing/0001564590-21-041571.json","markdown":"https://secwatch.observer/filing/0001564590-21-041571.md","text":"https://secwatch.observer/filing/0001564590-21-041571.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000156459021041571/0001564590-21-041571-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000156459021041571/enta-8k_20210805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T21:15:32.396041+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}